Quick Answer
NRX Pharmaceuticals, Inc. reported Operating Income of -$16.22 million for fiscal year 2025.
NRX Pharmaceuticals, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$16.22M | +12.3% |
| 2024 | -$18.50M | +33.5% |
| 2023 | -$27.84M | +37.2% |
| 2022 | -$44.34M | +61.7% |
| 2021 | -$115.80M | -125.3% |
| 2020 | -$51.39M | -7105.3% |
| 2019 | -$713.2K | +29.1% |
| 2018 | -$1.01M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$4.02M | -33.2% | -7.9% |
| June 30, 2025 | -$3.73M | +47.1% | -23.4% |
| September 30, 2024 | -$3.02M | +48.0% | +57.1% |
| June 30, 2024 | -$7.05M | +13.9% | -17.5% |
| March 31, 2024 | -$6.00M | -55.9% | -3.3% |
| September 30, 2023 | -$5.81M | +36.5% | +29.1% |
| June 30, 2023 | -$8.19M | +14.7% | -112.8% |
| March 31, 2023 | -$3.85M | +75.5% | +57.9% |
- NRX Pharmaceuticals, Inc. showed an increase of +12.3% in Operating Income compared to the prior fiscal year.
- Over the 2018–2025 period, NRX Pharmaceuticals, Inc.’s operating income has declined by 1511.9% (from -$1.01 million to -$16.22 million).
- The most recent figure is from NRX Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: